Axovant Sciences Ltd (NASDAQ:AXGT) – Equities researchers at Jefferies Financial Group increased their FY2019 earnings per share estimates for Axovant Sciences in a research report issued on Sunday, March 31st, according to Zacks Investment Research. Jefferies Financial Group analyst M. Yee now anticipates that the company will post earnings of ($1.12) per share for the year, up from their prior estimate of ($1.15). Jefferies Financial Group also issued estimates for Axovant Sciences’ Q4 2019 earnings at ($0.16) EPS, Q4 2020 earnings at ($0.15) EPS, FY2020 earnings at ($0.64) EPS and FY2021 earnings at ($0.61) EPS.
Several other analysts also recently commented on the company. Chardan Capital upgraded Axovant Sciences from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Monday, March 11th. JMP Securities reiterated an “outperform” rating and set a $6.00 target price (down from $8.00) on shares of Axovant Sciences in a research note on Monday, March 11th. Guggenheim started coverage on Axovant Sciences in a research note on Friday, February 15th. They set a “buy” rating and a $7.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Axovant Sciences in a research note on Tuesday, March 12th. Finally, Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $5.05.
Axovant Sciences (NASDAQ:AXGT) last issued its earnings results on Thursday, February 7th. The company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27).
About Axovant Sciences
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Further Reading: What is a Derivative?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.